COVID-19 and Rheumatology

COVID-19 and Rheumatology

Disclosures: The researchers report funding support from the NIH and a Bloomberg Philanthropies COVID-19 Response Initiative Grant. Izmirly reports consulting fees from GlaxoSmithKline and Momenta/Janssen. Please see the study for all other authors’ relevant financial disclosures.
August 24, 2021
2 min read
Save

Nearly 30% of patients with lupus show low response to COVID-19 vaccine

Disclosures: The researchers report funding support from the NIH and a Bloomberg Philanthropies COVID-19 Response Initiative Grant. Izmirly reports consulting fees from GlaxoSmithKline and Momenta/Janssen. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

About 29% of patients with systemic lupus erythematosus demonstrate low response to the COVID-19 vaccine, with immunosuppression therapy associated with decreased protection, according to data published in Arthritis & Rheumatology.

“This supports previous data that has been coming out from our group and others that show patients on certain immunosuppression have a blunted effect to the COVID-19 vaccine,” Peter M. Izmirly, MD, of the New York University Grossman School of Medicine, told Healio Rheumatology. “This study focused on patients only with systemic lupus erythematosus and showed that a lower response to the vaccine was independently associated with being on any immunosuppressive agent, with the exception of antimalarials such as hydroxychloroquine.”

About 29% of patients with systemic lupus erythematosus demonstrate low response to the COVID-19 vaccine, with immunosuppression therapy associated with decreased protection, according to data derived from Izmirly PM, et al. Arthritis Rheumatol. 2021;doi:10.1002/art.41937.

To analyze seroreactivity and disease flares in patients with SLE following COVID-19 vaccination, Izmirly and colleagues recruited participants from the New York University Lupus Cohort. According to the researchers, the cohort is a prospective convenience registry open to enrolling any adult with SLE seen at NYU Langone Health and Bellevue Hospital Center since 2014.

For their study, Izmirly and colleagues considered all adults with SLE who planned to receive any available COVID-19 vaccine. Exclusion criteria included unwillingness to provide blood after the second dose of the vaccine, incomplete vaccination schedule, or speaking a language other than English, Spanish or Mandarin. Healthy adults with no known rheumatic diseases and no immunosuppressive medications were recruited as controls.

Peter M. Izmirly

In all, the study included 90 patients with SLE and 20 healthy control participants, all of whom received a complete COVID-19 vaccine regimen. Among those with SLE, 79% were receiving hydroxychloroquine and 29% were on systemic glucocorticoids, with a mean dose of 7 mg of prednisone. In addition, 42% were using at least one immunosuppressant, with mycophenolate mofetil (MMF) being the most common at 21%, followed by belimumab at 11%. Approximately, 17% were on more than one immunosuppressant.

Izmirly and colleagues used IgG seroreactivity to the SARS-CoV-2 spike receptor-binding domain (RBD) and SARS-CoV-2 microneutralization to assess B-cell responses, as well as IFN- production to examine T-cell responses. They measured disease activity using the hybrid SLE disease activity index (SLEDAI), with flares classified based on the SELENA/SLEDAI flare index.

According to the researchers, 28.8% of patients with SLE demonstrated an IgG response below that of the lowest control — less than 100 units/ml. In their logistic regression analyses, the researchers found that any immunosuppressant or prednisone use, and a normal anti-dsDNA level prior to vaccination, were associated with decreased vaccine responses.

In addition, IgG seroreactivity to the SARS-CoV-2 Spike RBD strongly correlated with the coronavirus microneutralization titers and antigen-specific IFN- production.

IFN- production was similarly reduced in a subset of patients with poor antibody responses. Pre- and post-vaccination SLEDAI scores were similar.

Lastly, just 11.4% of patients experienced a disease flare following vaccination. Among the reported flares, 1.3% were severe.

“Overall, the proportion of patients who flared was low, and severe SLE flares were rare,” Izmirly said. “The results of this work are reassuring regarding the safety of initial vaccination and suggest further studies are needed to assess efficacy and safety of booster vaccination in patients with suboptimal responses to the standard vaccination regimen.”